ICON plc (ICLR) stock is expected to deviate a maximum of $11.31 from the average target price of $78 for the short term period. 6 Street Experts have initiated coverage on the stock with the most promising target being $87 and the most muted being $59.
ICON plc (ICLR) has an average broker rating of 2.2, which is interpreted as a Buy, as rated by 10 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
Also, Jefferies maintains its rating on ICON plc (NASDAQ:ICLR). The global brokerage major raises the current price target from $78 per share to $80 per share. Analysts at the Jefferies have a current rating of Hold on the shares. The rating by the firm was issued on July 27, 2016.
ICON plc (NASDAQ:ICLR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $77.00 and $76.22 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $77.25. The buying momentum continued till the end and the stock did not give up its gains. It closed at $76.85, notching a gain of 0.08% for the day. The total traded volume was 332,408 . The stock had closed at $76.79 on the previous day.
ICON public limited company (ICON) is an Ireland-based contract research organization (CRO), providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. ICONs services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. ICON also conducts various laboratory tests on the patients blood, urine and other bodily fluids at appropriate intervals during the trial. The Companys information systems offerings include ICONIK, Firecrest, iDOC, iLearn, ADDPLAN, AptivAdvantage and AptivInsite. ICON, through its subsidiaries, also provides payer-validated market access solutions, and clinical trial consulting and regulatory support.